Massive korean study maps the overlap of heart, kidney, and metabolic diseases
NCT ID NCT07673822
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No treatments are given—this is an observational study to better understand disease patterns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal how often these diseases occur together, helping doctors identify high-risk patients earlier.
- What could go wrong
- This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novo Nordisk Pharma Korea, Ltd.
Seoul, 01000, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can discarded bone reveal the secrets to stronger bones?
- Can a Two-Drug combo tip the scales against obesity?
- Aging kidneys under the microscope: could a simple test predict failure?
- Seaweed extract may tackle fatty liver Disease—A trial puts it to the test